Summer Movements and Impact of Individual Striped Skunks, Mephitis mephitis, on Duck Nests in Saskatchewan

Striped Skunks (Mephitis mephitis) are important predators of duck eggs in the Canadian prairies. We estimated the impact of individual Striped Skunks on duck nests by intensive observations of foraging movements and depredation of duck nests in southern Saskatchewan, 1993-1994. Nightly, skunk movements were variable (range 0-20 km per night), and did not differ among seasons for females, or between males and females during the parturition/rearing season. Overall, nightly movement of Striped Skunks averaged 7.4 km for females (SD = 5.9 km, n = 20 females) and 6.7 km for males (SD = 3.2 km, n = 5 males). During 1,873 h of radio-tracking, we observed depredation of 10 duck nests by 8 skunks (7 F, 1 M). Using our observed estimate of one depredation for every 187 h, and averaged nightly activity of 8-10 h per night, we estimated that individual skunks find one duck nest every 19-23 nights. Thus, during the 60-day nesting season for ducks (mid-May to mid-July), individual skunks probably find 2-3 duck nests. These observations reinforce the growing evidence that, at normal duck nest densities (<2.5 nests/ha), depredation of eggs by Striped Skunks is opportunistic, and the impact of Striped Skunks on duck nests is a direct function of Striped Skunk abundance

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Background Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. Methods FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762. Findings Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839–1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26–6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38–2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months. Interpretation Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function. Funding UK Stroke Association and NIHR Health Technology Assessment Programme

Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

We characterized the role of structural variants, a largely unexplored type of genetic variation, in two non-Alzheimer’s dementias, namely Lewy body dementia (LBD) and frontotemporal dementia (FTD)/amyotrophic lateral sclerosis (ALS). To do this, we applied an advanced structural variant calling pipeline (GATK-SV) to short-read whole-genome sequence data from 5,213 European-ancestry cases and 4,132 controls. We discovered, replicated, and validated a deletion in TPCN1 as a novel risk locus for LBD and detected the known structural variants at the C9orf72 and MAPT loci as associated with FTD/ALS. We also identified rare pathogenic structural variants in both LBD and FTD/ALS. Finally, we assembled a catalog of structural variants that can be mined for new insights into the pathogenesis of these understudied forms of dementia

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Habitat loss, not fragmentation, drives occurrence patterns of Canada lynx at the southern range periphery.

Peripheral populations often experience more extreme environmental conditions than those in the centre of a species' range. Such extreme conditions include habitat loss, defined as a reduction in the amount of suitable habitat, as well as habitat fragmentation, which involves the breaking apart of habitat independent of habitat loss. The 'threshold hypothesis' predicts that organisms will be more affected by habitat fragmentation when the amount of habitat on the landscape is scarce (i.e., less than 30%) than when habitat is abundant, implying that habitat fragmentation may compound habitat loss through changes in patch size and configuration. Alternatively, the 'flexibility hypothesis' predicts that individuals may respond to increased habitat disturbance by altering their selection patterns and thereby reducing sensitivity to habitat loss and fragmentation. While the range of Canada lynx (Lynx canadensis) has contracted during recent decades, the relative importance of habitat loss and habitat fragmentation on this phenomenon is poorly understood. We used a habitat suitability model for lynx to identify suitable land cover in Ontario, and contrasted occupancy patterns across landscapes differing in cover, to test the 'threshold hypothesis' and 'flexibility hypothesis'. When suitable land cover was widely available, lynx avoided areas with less than 30% habitat and were unaffected by habitat fragmentation. However, on landscapes with minimal suitable land cover, lynx occurrence was not related to either habitat loss or habitat fragmentation, indicating support for the 'flexibility hypothesis'. We conclude that lynx are broadly affected by habitat loss, and not specifically by habitat fragmentation, although occurrence patterns are flexible and dependent on landscape condition. We suggest that lynx may alter their habitat selection patterns depending on local conditions, thereby reducing their sensitivity to anthropogenically-driven habitat alteration

Summary of the amount of suitable land cover and habitat fragmentation across two regions in the southern boreal forest in Ontario, Canada.

a<p>Land cover is the amount of suitable land cover measured at the landscape level as determined by the habitat suitability model.</p><p>Summary of the amount of suitable land cover and habitat fragmentation across two regions in the southern boreal forest in Ontario, Canada.</p

Mean percentage of suitable habitat (with standard errors) for lynx presences compared to pseudo-absences at the 25 km² scale in the regions of Chapleau and Mississagi with three levels of suitable land cover.

<p>Mean percentage of suitable habitat (with standard errors) for lynx presences compared to pseudo-absences at the 25 km² scale in the regions of Chapleau and Mississagi with three levels of suitable land cover.</p

Habitat suitability map for Canada lynx in (A) central Ontario with Regions outlined and (B) suitable land cover levels within each region, as determined by the literature-based habitat suitability model.

<p>Habitat suitability map for Canada lynx in (A) central Ontario with Regions outlined and (B) suitable land cover levels within each region, as determined by the literature-based habitat suitability model.</p